SR1555 is a selective RORγ inverse agonist (IC50=1.5 uM) that suppresses T(H)17 cells and stimulates T regulatory cells.

SR-16430 is a selective ORL1 receptor (NOP receptor) antagonist that has 10-fold selectivity over μ-opioid receptor..

SR-16435 is a mixed NOP/μ-opioid partial agonist with equally high affinity (Ki=29 nM) for both NOP and μ-opioid receptors.

SR-16507 is a potent full agonist of ORL1 receptor (NOP receptor) and partial agonist of mu-opioid receptor with Ki of 5.22 nM and 1.07 nM, respectively.

SR-16835 is a potent full agonist of ORL1 receptor (NOP receptor) with binding Ki of 11.4 nM, with low-affinity mu-opioid partial agonist activity (Ki=79.9 nM).

SR17018 is a Mu opioid agonists which was made to promote signaling through G proteins or barrestin2.

SR31527 is a novel allosteric Kinesin-like protein KIFC1 inhibitor that inhibits microtubule-stimulated KIFC1 ATPase activity with IC50 of 6.6 uM, binds directly to KIFC1 with Kd of 25.4 nM.

SR-3306 is a highly selective, brain penetrant, potent inhibitor of JNK with IC50 of 67, 283 and 159 nM for JNK1, JNK2 and JNK3, >100-fold selectivity over p38.

SR3335 (ML-176) is a selective RORα synthetic ligand, directly binds to RORα, but not other RORs, and functions as a selective partial inverse agonist of RORα in cell-based assays.

SR-57227 is a high affinity, selective 5-HT3 receptor agonist, demonstrates anticonvulsant effects in vivo..

SR-57227 is a high affinity, selective 5-HT3 receptor agonist, demonstrates anticonvulsant effects in vivo..

SR7826 is a potent and selective LIM kinase (LIMK) inhibitor with IC50 of 43 nM, displays >100-fold selectivity over ROCK1 and ROCK2, as well as JNK kinases (>400-fold).

SR9009 is an agonist of REV-ERB with IC50 = 670 nM for REV-ERBα and IC50 = 800 nM for REV-ERBβ.

SR9011 is a REV-ERBα/β agonist with IC50s of 790 nM and 560 nM for REV-ERBα and REV-ERBβ, respectively.

SRI 37892 (SRI37892) is a novel potent, small molecule Frizzled 7 (Fzd 7) inhibitor with IC50 of 0.66 uM in Wnt/β-catenin assay.

SRI31215 2TFA is a small molecule that acts as a triplex inhibitor of matriptase, hepsin and HGFA and mimics the activity of HAI-1/2.

SRPIN340 is a selective SRPK inhibitor with Ki of 0.89 μM for SRPK1, showing no significant inhibitory activity against more than 140 other kinases..

SRPKIN-1 is a covalent and irreversible SRPK1/2 inhibitor with IC50s of 35.6 and 98 nM, respectively. Anti-angiogenesis effect.

SRT 2183 is a potent, selective SIRT1 activator with EC1.5 of 0.36 uM, displays good selectivity for activation of SIRT1 versus SIRT2 and SIRT3 (EC1.5>300 uM) and is more potent than Resveratrol.

SRT1460 is a potent, selective SIRT1 activator with EC1.5 of 2.9 uM, displays good selectivity for activation of SIRT1 versus SIRT2 and SIRT3 (EC1.5>300 uM) and is more potent than Resveratrol.

SSE15206 is a microtubule depolymerizing agent that overcomes multidrug resistance.

SSR125543 (Crinecerfont, SSR-125543) is a potent, nonpeptide, orally active corticotropin-releasing factor (CRF) receptor CRF1 antagonist, shows anxiolytic- and antidepressant-like activities in vivo. .

SSR128129E is an orally-active and allosteric FGFR1 inhibitor with IC50 of 1.9 μM, while not affecting other related RTKs.

SSR-240612 is a bradykinin B1 receptor antagonist potentially for the treatment of chronic pain.

SSR411298 is a highly selective, brain penetrant and orally-active inhibitor of FAAH with IC50 of 62.5 nM (mouse brain FAAH).

ST-148 a novel potent, broad-spetrum inhibitor of dengue virus (DENV) replication, inhibits DENV-2 wth EC50 of 16 nM in viral titer reduction assays, interacts with the DENV Capsid protein.

ST-162 is a potent, bifunctional MAPK/PI3K antagonist with IC50 of 191 nM and 398 nM for PI3Kα and MEK1, respectively.

ST-168 is a novel potent, orally available MEK/PI3K bifunctional inhibitor with IC50 of 182, 69.2, 1482, 2293, and 41.7 nM for MEK1, PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ, respectively.

ST3932 is a metabolite of ST1535, acts as an antagonist of adenosine A2A receptor, with Kis of 8 nM and 33 nM for A2A and A1 receptors, respectively.

STA 2842 (STA2842) is a highly specific inhibitor of HSP90 (IC50=135 nM, HSP90α) that competitively binds the N-terminal ATP pocket of HSP90.

Stachyose is a prebiotic, a non-reducing tetrasaccharide in the rafnose family of oligosaccharides with few side efects.

Stafib-2 (Stafib 2) is a potent, selective small molecule inhibitor of transcription factor STAT5b with Ki of 9 nM, >20-fold selectivity over STAT5a..

STAT5b inhibitor 7 (Capstafin prodrug) is the pivaloyloxymethyl ester prodrug of Capstafin, which is a potent, selective STAT5b inhibitor with Ki of 0.34 uM.

Statil is shown to be a potent aldose reductase inhibitor.

Stattic, the first nonpeptidic small molecule, potently inhibits STAT3 activation and nuclear translocation with IC50 of 5.1 μM, highly selectivity over STAT1.

Stavudine is a nucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.

STD-101-D1 is a novel brain permeable, G protein-biased beta-1 adrenergic receptor (ADRB1) partial agonist with EC50 of 16.9 nM.

STD1T (USP2a inhibitor STD1T) is a hit-to-lead, small-molecule inhibitor of USP2a with IC50 of 3.3 uM in Ub-AMC assays, displays no activity against USP7 at 10 uM.

Stearic acid is a long chain dietary saturated fatty acid which exists in many animal and vegetable fats and oils.

Stearoylcarnitine is a fatty ester lipid molecule.

StemRegenin 1 antagonizes hematopoietic stem cell differentiation.

Steviolbioside is a natural sweetener, it presents notable inhibition on human hepatocarcinoma cell Hep3B, human breast cancer cell MDA-MB-231 and human pancreatic cancer cell BxPC-3

Stibogluconate sodium (Sodium stibogluconate) is a multiple antimony compound that has leishmanicidal and potential antineoplastic activities, inhibits protein tyrosine phosphorylase SHP-1 (99% inhibtion at 10 ug/mL), SHP-2 and PTP1B, shows anticancer act

STIMA 1 is a small molecule mutant p53 reactivator that can stimulate mutant p53 DNA binding in vitro, induces expression of p53 target proteins and triggers apoptosis in mutant p53-expressing human tumor cells..

STING agonist 4 is an amidobenzimidazole (ABZI)-based compound that functions as a STING agonist with Kd of 1.6 nM (binding of endogenous full-length STING, THP-1 cell lysates); caused dose-dependent phosphorylation of IRF3 and STING that was inhibited by the TBK1 inhibitor BX795, induced dose-dependent secretion of IFN-β with EC50 of 3.1 uM in PBMCs (18-fold more potent than cGAMP); promotes production of IFN-γ-induced protein 10 (IP-10), IL-6 and TNFα by a mechanism that is dependent on STING-mediated activation of TBK1; unlike cGAMP and DMXAA, compound 2 efficiently activates STING function while maintaining an open STING confirmation.

STK16-IN-1 is a STK16 kinase inhibitor with an IC50 of 295 nM.

STK321130（FLT3-IN-2）is potent FLT3 inhibitor

STO-609 is a cell-permeable inhibitor of calcium/calmodulin-dependent kinase kinases (CaMKK) isoforms CaMKKα and CaMKKβ (Ki = 80 and 15 ng/ml, respectively).

Streptomycin (Agrept) is an effective antibiotic against M. tuberculosis, is used for the research of tuberculosis (TB). Streptomycin also is a bacteriocidal agent that can be used for the research of a number of bacterial infections. Streptomycin can bind strongly to nucleic acids, interferes and blocks protein synthesis while permitting continued RNA and DNA synthesis. Streptomycin, as a common antibiotic used in culture media, also is a blocker of stretch-activated and mechanosensitive ion channels in neurons and cardiac myocytes .

Streptomycin sulfate

Streptonigrin (Bruneomycin, NSC 45383) is a potent, selective, and irreversible PAD4 inactivator with IC50 of 1.87 uM, also binds directly to RAD54 with Kd of 9.1 uM, inhibits ATPase and DNA branch migration activity of RAD54.

S-Trityl-L-cysteine (NSC 83265) is a potent, cell-permeable, selective inhibitor of mitotic kinesin Eg5, inhibits basal ATPase activity (IC50=1 mM) and microtubule-activated ATPase activity of Eg5 (IC50=140 nM).

SU 16f is a potent and selective PDGFRβ inhibitor with IC50 of 10 nM, displays >14-fold, >229-fold and >10,000-fold selectivity over VEGFR2, FGFR1 and EGFR respectively.

SU 4313 is a bioactive chemical.

SU 4942 is a bioactive chemical.

SU 6656 is a selective inhibitor of Src kinases, Including Src, Yes, Lyn, and Fyn (IC50 = 280, 20, 130, 170 nM, respectively).

SU-11752 is a potent, selective inhibitor of DNA-PK, >500-fold selectivity over PI3Kγ, inhibits DNA double-strand break repair in cells and sensitizs ionizing radiation in cancer cells..

SU5614 is a potent and selective FLT3 inhibitor.

SU-909 (SU909, IKKα-IN-48) is a potent, selective IKKα inhibitor with Ki of 0.08±0.07 uM, 10-20-fold selectivity over IKKβ (IC50=1.0±0.28 uM); inhibits FCS-stimulated phosphorylation of p100 in U2OS cells with IC50 of 8.8 uM, inhibits the noncanonical NF-kB pathway without affecting IKKβ-dependent IKappa-Bα loss in the canonical pathway.

Suberohydroxamic acid is a competitive HDAC inhibitor with IC50 values of 0.25 and 0.3 μM for HDAC1 and HDAC3 respectively.

Suberylglycine is an acyl glycine, which is a normally minor metabolite of fatty acid.

Suc-AAP-Abu-pNA is a chromogenic peptide substrate for pancreatic elastase.It is cleaved by elastase to release p-nitroalinide (p-NA), which can be quantified by colorimetric detection at 405 nm as a measure of enzyme activity.

Succinobucol is a phenolic antioxidant with anti-inflammatory and antiplatelet effects.

Sucralfate is a sucrose sulfate-aluminium complex that binds to the ulcer, creating a physical barrier that protects the gastrointestinal tract from stomach acid and prevents the degradation of mucus

Sucralose is a low-calorie artificial sweetener.

Suc-YVAD-pNA is a colorimetric substrate for caspase-1/interleukin-1β-converting enzyme (ICE) and caspase-4.

Sudemycin E is an alternative splicing inhibitor that binds to the U2 small nuclear ribonucleoprotein (snRNP) component SF3B1, causes a rapid change in alternative pre-messenger RNA splicing.

Sudemycin K is a synthetic antitumor splicing inhibitor with IC50 of 15 nM (MCL1 alternative splicing regulation), shows cytotoxicity in HeLa cells with IC50 of 2.3 nM.

Sulbactam

Sulbactam sodium (Unasyn)

Sulfabenzamide is an antibacterial/antimicrobial which also exhibit their antitumor effects through multiple mechanisms including inhibition of membrane bound carbonic anhydrases, prevention of microtubule assembly, cell cycle arrest, and inhibition of an

Sulfadoxine (Sulphadoxine)

Sulfameter (Bayrena)

Sulfamethizole (Proklar)

Sulfasalazine, a sulfa agent and a derivative of mesalazine, is used primarily as an anti-inflammatory agent.

Sulfathiazole is an organosulfur compound that has been used as a short-acting sulfa drug.

Sulfatinib (HMPL-012) is a potent, multi-targeted tyrosine kinase inhibitor of VEGFR-1/2/3, FGFR1, CSF1R with IC50 of 2/24/1 nM, 15 nM, 4 nM, respectively.

Sulindac (Clinoril)

Sulisobenzone is an ingredient in some sunscreens which protects the skin from damage

Sumanirole maleate(PNU 95666E; U95666E) is a highly selective D2 receptor full agonist with an ED50 of about 46 nM.

Sunifiram (DM-235) is a piperazine derived ampakine-like drug which has nootropic effects in animal studies with significantly higher potency than piracetam.

Super-TDU is an inhibitory peptide targeting YAP-TEADs interaction.

Suprofen (Profenal)

Surfen hydrate is a small molecule antagonist of heparan sulfate, binds to heparin, low molecular weight heparins, and to HS and other GAGs.

Surfen is a small molecule antagonist of heparan sulfate, binds to heparin, low molecular weight heparins, and to HS and other GAGs.

SUVN-502 (SUVN502) is a potent, selective, brain penetrant and orally active 5-HT6 receptor antagonist with Ki of 2.04 nM.

SUVN-502 (SUVN502) is a potent, selective, brain penetrant and orally active 5-HT6 receptor antagonist with Ki of 2.04 nM.

SUVN-502 (SUVN502, Masupirdine) is a potent, selective, brain penetrant and orally active 5-HT6 receptor antagonist with Ki of 2.04 nM.

SUVN-G3031 (SUVN-G 3031) is a potent, selective, orally active histamine H3 receptor (H3R) inverse agonist with Ki of 8.73 nM (hH3R).

SUVN-G3031 (SUVN-G 3031) is a potent, selective, orally active histamine H3 receptor (H3R) inverse agonist with Ki of 8.73 nM (hH3R).

SW-034538 is a potent TAOK2 (Thousand-And-One Kinase 2.

SW-083688 (SW083688) is a potent, highly selective TAOK2 (Thousand-And-One Kinase 2, MAP3K17) inhibitor with IC50 of 1.3 uM.

SW-100 (SW100) is a potent, selective, brain penetrable HDAC6 inhibitor with IC50 of 2.3 nM, displays >1,000-fold selectivity over all other class I, II, and IV HDAC isoforms.

Gliocidin is a prodrug that is anabolized into its tumoricidal metabolite, gliocidin–adenine dinucleotide (GAD). Gliocidin kills glioblastoma cells while sparing non-tumour replicative cells. Gliocidin activity targets a de novo purine synthesis vulnerability in glioblastoma through indirect inhibition of inosine monophosphate dehydrogenase 2 (IMPDH2). Gliocidin penetrates the blood–brain barrier and extends the survival of mice with orthotopic glioblastoma.

SW-163D-AcLysValCit-PABC-DMAE is a Drug-Linker Conjugates for ADC which consists of a natural bis-intercalator, SW-163D, conjugated via an AcLysValCitPABC-DMAE linker.

SY-1365 is a CDK7 inhibitor. In vitro, SY-1365 inhibited cell growth of many different cancer types at nanomolar concentrations.

SYC-435 (SYC435) is a potent inhibitor of mutant IDH1, binds at the isocitrate pocket of mutated IDH1 with Ki values of 190 nM against IDH1 R132H and 120 nM against IDH1 R132C.

Syk inhibitor II is a cell-permeable, pyrimidine-carboxamide compound that selectively and reversibly blocks Syk (IC50 = 41 nM) in an ATP-competitive manner.

Syk-IN-23 is a potent, selective Syk kinase inhibitor with IC50 of 20 nM, possesses good PK in both rat and dog and demonstrated efficacy in rat CIA model..

Syn-TEF1 intermediate 1 is a chemcal intermediate for Syn-TEF1 synthesis, which is a molecule actively enables transcription across repressive GAA repeats that silence frataxin expression in Friedreich's ataxia..

Syn-TEF1 is a molecule actively enables transcription across repressive GAA repeats that silence frataxin expression in Friedreich's ataxia, license transcription elongation at targeted genomic loci.

SynuClean-D (SC-D) is a novel, small molecule inhibitor of α-synuclein (α-Syn) aggregation, incubation of 70 uM α-Syn with 100 uM SC-D impacted α-Syn aggregation in vitro, as monitored by Th-T fluorescence.

T-025 (T025, CLK inhibitor T-025) is an orally available, potent inhibitor of Cdc2-like kinases (CLKs) with Kd of 4.8, 0.096, 6.5, and 0.61 nM for CLK1, CLK2, CLK3, and CLK4, also inhibits DYRK1A and DYRK1B with IC50 of 0.074 and 1.5 nM.

T-1105 is a broad-spectrum antiviral inhibitor that demonstrates good activity for various RNA viruses, including influenza virus, arenaviruses, bunyaviruses, West Nile virus (WNV), yellow fever virus (YFV), FMDV, and ZIKV.

T-155535 is a small molecule inhibitor that effectively inhibits the β-catenin/Tcf4 interaction with Ki of 21 uM in AlphaScreen assay.

T16Ainh-A01 is an inhibitor of the calcium-activated chloride channel TMEM16A, inhibits Ca2+-activated Cl− channel (CACC) activity in TMEM16A-transfected FRT cells with IC50 of 1 uM; T16Ainh-A01 (1-30 uM) inhibited single calcium (Ca2+)-activated chloride (Cl−) channels and whole cell currents activated by 500 nM free Ca2+; T16Ainh-A01 relaxed mouse thoracic aorta pre-contracted with methoxamine with an IC50 of 1.6 uM and suppressed the methoxamine concentration-effect curve; blocks calcium-activated chloride channels in vascular smooth muscle cells and relaxes murine and human blood vessels.

T-1840383 is a potent, ATP-competitive, dual c-Met/VEGFR-2 inhibitor with IC50 of 1.9, 7.7, 2.2 and 5.5 nM for c-Met, VEGFR1, 2 and 3, respectively.

T-226296 is a potent, selective, non-peptide antagonist of MCHR1 (Melanin-concentrating hormone receptor 1) with IC50 of 5.5 nM and 8.6 nM for human and rat MCHR1, respectively.

T-26c is highly potent and selective matrix metalloproteinase-13 (MMP-13) inhibitor with an IC50 of 6.75 pM and more than 2600-fold selectivity over the other related metalloenzymes.

T-3861174 is a novel small molecule prolyl tRNA synthetase (PRS) with binding IC50 of 2.3 nM.

T3D 959 (DB-959) is a potent, brain penetrant, orally active dual PPARδ/PPARγ agonist with EC50 of 19/297 nM, respectively.

T-448 (T448) is a specific inhibitor of LSD1 enzyme activity, enhances H3K4 methylation in primary cultured rat neurons but has little impact on LSD1-GFI1B complex in human TF-1a erythroblasts.

T-448 free base (T448) is a specific inhibitor of LSD1 enzyme activity, enhances H3K4 methylation in primary cultured rat neurons but has little impact on LSD1-GFI1B complex in human TF-1a erythroblasts.

T-521 is a novel PLK1 PBD (Polo-box domain) inhibitor that specifically inhibits the PBD of PLK1 (IC50=1.22 uM), but not those of Plk2-3.

T5342126 hydrochloride is a potent, selective TLR4 inhibitor, inhibits LPS-induced NO production in RAW 264 macrophage cells with IC50 of 27.8 uM.

T5342126 is a potent, selective TLR4 inhibitor, inhibits LPS-induced NO production in RAW 264 macrophage cells with IC50 of 27.8 uM.

T5910047 (T-5910047) is a small molecule inhibitor of MyD88-dependent signaling pathways, disrupts MyD88 homodimeric formation; inhibits SEB-induced inhibition of cytokine production in PBMCs with IC50 of 2-10 uM, also inhibits SEA-induced pro-inflammatory cytokine production, shows no toxicity in primary cells up to 100 uM.

T6167923 (T-6167923) is a small molecule inhibitor of MyD88-dependent signaling pathways, disrupts MyD88 homodimeric formation.

Tabersonine is a terpene indole alkaloid found in the medicinal plant Catharanthus roseus.

Tafamidis is a novel specific transthyretin (TTR) stabilizer or dissociation inhibitor.

Tafamidis is a novel specific transthyretin (TTR) stabilizer or dissociation inhibitor.

Tafenoquine (SB-252263, Tafenoquine, WR 238605) is a long-acting, orally active anti-malarial agent to prevent malaria that is holoendemic for Plasmodium falciparum..

Tafenoquine succinate (SB-252263, Tafenoquine, WR 238605) is a long-acting, orally active anti-malarial agent to prevent malaria that is holoendemic for Plasmodium falciparum..

TAI-95 (TAI 95) is a potent, orally abioavailable Hec1 inhibitor that disrupts Hec1-Nek2 protein interaction wide anti-cancer spectrum (GI50=14.29-73.65 nM, breast cancer cell lines).

TAK 1 inhibitor

TAK-100 is a potent, selective and orally active inhibitor of DPP-4 with IC50 of 5.3 nM, shows no inhibition on DPP2/8/9..

TAK1-IN-1 is a potent, selective, Type I (ATP-competitive, DFG-in) TAK1 inhibitor with Kd of 59 nM, a thienopyrimidine scaffold that serves as a good starting point for medicinal chemistry..

TAK-599 is a highly promising parenteral cephalosporin targeted for MRSA infection.

TAK-659 (TAK659, Mivavotinib) is a potent, selective and orally available SYK inhibitor with IC50 of 3.2 nM.

TAK-700 shows potent inhibitory activity against rat, monkey, and human steroid 17,20-lyase inhibitor with IC50 of 54 nM, 27 nM, and 38 nM, respectively.

TAK-828F is a potent, selective, and orally available retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonist (binding IC50=1.9 nM, reporter gene IC50=6.1 nM). TAK-828F shows excellent ROR isoforms selectivity (>5000-fold selectivity aga

TAK-931 (Simurosertib) is a potent, selective, ATP competitive and orally bioavailable inhibitor of Cdc7 with IC50 of <0.3 nM.

TAK-960 is a novel, potent and selective Polo-like kinase 1 (PLK1) inhibitor.

Talabostat (PT-100, Val-boroPro) is a potent, nonselective, orally available inhibitor of post-proline cleaving serine proteases with Ki of 0.18 nM for DPP4, also potently inhibits DPP8/9 (IC50=1.5/0.76 nM), FAP, DPP2 and some other DASH family enzymes.

Tamibarotene(Am-80) is a retinoic acid receptor α (RARα) agonist that induces differentiation (ED50 = 0.79 nM) and apoptosis of HL-60 cells in vitro.

TAM-IN-1 is a highly potent, macrocyclic inhibitor of Mer and Axl with Ki of <50 pM and 130 pM, respectively..

Taminadenant is an adenosine receptor A2a antagonist..

Tamoxifen(ICI-46474) is an antagonist of the estrogen receptor in breast tissue via its active metabolite, hydroxytamoxifen.

Tamsulosin hydrochloride((R)-(-)-YM12617;LY253351) is a selective α1 receptor antagonist.

Tanshinone I is an inhibitor of type IIA human recombinant sPLA2 (IC50=11 μM) and rabbit recombinant cPLA2 (IC50=82 μM).

TAOK inhibitor 43 is a novel potent, selective, ATP-competitive TAO Kinase (TAOK) inhibitor with IC50 of 11 and 15 nM against TAOK1 and TAOK2, respectively; increases the mitotic population, the percentages of mitotic cells displaying amplified centrosomes and multipolar spindles, induces cell death, and inhibits cell growth in centrosome-amplified SKBR3 or BT549 breast cancer cell models.

TAOK inhibitor 63 is a novel potent, selective, ATP-competitive TAO Kinase (TAOK) inhibitor with IC50 of 19 and 39 nM against TAOK1 (MAP3K16) and TAOK2 (MAP3K17), respectively.

TAP-311 is a novel potent and selective CETP inhibitor with plasma IC50 of 62 nM.

TAPI-1 is a specific TACE(TNF-α-converting enzyme) inhibitor.

Tarafenacin(SVT-40776) is a highly selective M3 muscarinic receptor antagonist (Ki= 0.19 nM), ~200 fold selectivity over M2 receptor.

Tarafenacin(SVT-40776) is a highly selective M3 muscarinic receptor antagonist (Ki= 0.19 nM), ~200 fold selectivity over M2 receptor.

Target Protein-binding moiety 6 hydrochloride is a compound that binds to BRD9, and used for inhibiting BRD9 activity, based on PROTAC.

Targocil is a novel antibiotics against Methicillin-resistant Staphylococcus aureus (MRSA).

TAS05567 (TAS-5567) is a novel potent, selective, orally available Spleen tyrosine kinase (Syk) inhibitor with IC50 of 0.37 nM.

TAS0728 (TAS-0728, TAS 0728) is a potent, selective, covalent, orally available inhibitor of HER2 kinase with IC50 of 36 nM in in vitro kinase assays.

TAS-102 is a novel oral combination drug that consists of an antineoplastic thymidine-based nucleoside analog, trifluorothymidine, and a potent thymidine phosphorylase inhibitor, tipiracil, in a 1:0.5 molar ratio.

TAS-114 is a first-in-class, potent, dual dUTPase/DPD inhibitor with Ki of 0.13/2.14 uM, respectively.

Pamufetinib (TAS-115) is a potent VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase inhibitor with IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively.

TAS-117 is a highly selective, non-ATP competitive pan-Akt inhibitor with IC50 of 4.8/1.6/44 nM for Akt1/Akt2/Akt3 respectively.

TAS-117 is a potent, selective, allosteric inhibitor of Akt with IC50 of 4.8/1.6/44 for Akt1/2/3, respectively.

Tasisulam (LY 573636) is a small molecule antitumor agent that induces apoptosis via the intrinsic pathway, resulting in cytochrome c release and caspase-dependent cell death.

Tasosartan is a long-acting angiotensin II (AngII) receptor blocker. Its long duration of action has been attributed to its active metabolite enoltasosartan. It is used to treat patients with essential hypertensionFor the detailed information of Tasosartan, the solubility of Tasosartan in water, the solubility of Tasosartan in DMSO, the solubility of Tasosartan in PBS buffer, the animal experiment (test) of Tasosartan, the cell expriment (test) of Tasosartan, the in vivo, in vitro and clinical trial test of Tasosartan, the EC50, IC50,and Affinity of Tasosartan, Please contact DC Chemicals..

TASP0376377 is a potent, selective prostaglandin D2 receptor (CRTH2) antagonist with binding IC50 of 19 nM.

Taspoglutide is a glucagon-like peptide-1(GLP-1) agonist for treatment of type 2 diabetes.

Tat-NR2B9c (NA-1) is a neuroprotective agent.

Tazarotene (Avage)

Tazarotenic Acid is an agent that acts as the principle active metabolite

TB500-2 is one of the TB500 metabolites. TB500 is a synthetic version of an active region of thymosin β4. TB500 is claimed to promote endothelial cell differentiation, angiogenesis in dermal tissues, keratinocyte migration, collagen deposition and decreas

TBB(NSC 231634) is a highly selective, ATP/GTP-competitive inhibitor of casein kinase-2 (CK2)with IC50s of 0.9 and 1.6 μM for rat liver and human recombinant CK2 respectively).

TBK1-IKKε inhibitor II is a potent, selective dual inhibitor of TBK1/IKKε with IC50 of 13 nM/59 nM, respectively.

TBOPP is a selective inhibitor of Rac-specific guanine nucleotide exchange factor DOCK1, inhibits DOCK1-mediated Rac activation with IC50 of 8.4 uM.

TBZE-029 is a selective inhibitor of the replication of several Enteroviruses with IC50 of 1.2 uM against coxsackievirus B3 replication, targets nonstructural protein 2C..

TC-DAPK 6 is an oxazalone compound that acts as a potent, ATP-competitive, and highly selective death-associated protein kinase (DAPK) inhibitor (IC50 = 69 and 225 nM against DAPK1 and DAPK3, respectively, with 10 uM ATP).

TCID is a selective ubiquitin C-terminal hydrolase-L3 (UCH-L3) inhibitor with IC50 of 0.6 uM, displays >100-fold selectivity over UCH-L1.

TCN238 is a positive allosteric mGlu4 receptor modulator with an EC50 of 1 μM.

TCS 359, a 2-acylaminothiophene-3-carboxamide, is a potent inhibitor of FLT3 with IC50 of 42 nM.

TCS 401 is a potent, selective inhibitor of protein-tyrosine phosphatase 1B (PTP1B) with Ki of 0.29 uM, weakly inhibits the protein phosphatases CD45 D1D2, PTPβ, PTPε D1, SHP-1, PTPα D1, and LAR D1D2 with Ki of 59, 560, 1,100, >2,000, >2,000, and >2,000 u

TCS 5861528 is a TRPA1 channel blocker and an antagonizer of AITC- and 4-HNE-evoked calcium influx.

TCS-JNK-5a is a selective inhibitor of JNK2 and JNK3 (pIC50 values are 6.7, 6.5, <5.0 and <4.8 for JNK3, JNK2, JNK1 and p38α respectively).

TD-0212 (TD0212) is a potent, orally efficacious, dual AT1 antagonist/Neprilysin (NEP) inhibitor with pKi of 8.9 (AT1) and pIC50 of 9.2 (NEP).

TD-198946(TD198946 ) is a small molecule stimulator of chondrogenesis; promotes chondrocyte differentiation.

TD-6450 is a next generation, potent HCV NS5A inhibitor that has potent antiviral activity against HCV infection..

TDI-2760 si a small molecule Aβ-aggregation inhibitor that not only shows a strong inhibitory efficacy toward the Aβ-fibrinogen interaction (IC50=1.67 uM) but also retains potency toward the Aβ42 aggregation inhibition process.

Tebipenem pivoxil(L-084)

Tecalcet (R-568.

Tecalcet (R-568.

Tecovirimat (ST-246, Tpoxx) is a potent, orally bioavailable, first-in-class inhibitor of orthopoxvirus egress with EC50 of 0.01-0.6 uM against a panel of Orthopoxviruses; ST-246 is active against multiple orthopoxviruses, including vaccinia, monkeypox, c

TED-347 (TED347) is an irreversible inhibitor of TEAD4-Yap1 protein-protein interaction (EC50=5.9 uM in FP asssays) via covalent modification of conserved cysteine (Cys367, Ki=1.3 uM), inhibits its binding to Yap1, blocked its transcriptional activity.

Tedizolid is the active moiety of the prodrug tedizolid phosphate, with high potency against Gram-positive species.

Tegatrabetan (BC-2059, BC2059, Tegavivint) is an orally bioavailable β-catenin antagonist that disrupts the binding of β-catenin to TBL1 and promotes β-catenin degradation, attenuates nuclear and cytoplasmic levels of β-catenin.

Teglicar, in vitro and in animal models, reduces gluconeogenesis and improves glucose homeostasis, refreshing the interest in selective and reversible L-CPT1 inhibition as a potential antihyperglycemic approach.

Tegoprazan, a potassium-competitive acid blocker, is a potent, oral active and highly selective inhibitor of gastric H+/K+-ATPase that could control gastric acid secretion and motility, with IC50 values ranging from 0.29-0.52 μM for porcine, canine, and human H+/K+-ATPases in vitro.

Teicoplanin Complex is a complex of antibiotics produced by Actinoplanes teichomyceticus. Teicoplanin, the major component of Teicoplanin Complex, is a glycopeptide antibiotic structurally similar to Vancomycin (sc-204938) and Ristocetin (sc-202318). As a

Telbivudine (Tyzeka, Sebivo) is an antiviral agent used in the treatment of hepatitis B infection.

Telithromycin (Ketek)

Telmisartan is an angiotensin II receptor antagonist that inhibits the angiotensin II AT1 receptor.

Telotristat (LP-778902) is a potent, small-molecule inhibitor of peripheral serotonin synthesis, acts by inhibiting tryptophan hydroxylase (TPH) with IC50 of 28 nM, demonstrates potential for the treatment of carcinoid syndrome..

Telratolimod (MEDI 9197, 3M 052) is a novel, injectable, tissue-retained TLR7/8 agonist that forms a tissue depot with gradual, sustained release, allowing local TLR triggering activity without systemic cytokine release.

TEMPOL (4-Hydroxy-TEMPO) is a superoxide scavenger that displays neuroprotective, anti-inflammatory and analgesic effects.

Tenapanor (AZD-1722;RDX5791) is a potent, selective inhibitor of the Na+/H+ exchanger 3 (NHE3) with IC50 of 5 and 10 nM for human and rat NHE3, respectively.

Teneligliptin is a novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor; competitively inhibited human plasma, rat plasma, and human recombinant DPP-4 in vitro, with IC50 values of approximately 1 nM.

Teneligliptin is a novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor; competitively inhibited human plasma, rat plasma, and human recombinant DPP-4 in vitro, with IC50 values of approximately 1 nM. IC50 value: 1 nM [1] Target: DPP4 in vi

Teniposide (Vumon)

Tenofovir disoproxil fumarate belongs to nucleotide analogue reverse transcriptase inhibitors (nRTIs).

Tenofovir exalidex is a novel lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir.